{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041982","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.009077+00:00","generated_at":"2026-06-07T23:18:14.590413+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bone Biologics announces registered direct offering of 1.14M shares at $0.64/share, with warrants","bullets":["Gross proceeds ~$729,200; net proceeds ~$591,000 after fees.","Warrants to purchase up to 1,139,063 shares at $0.52/exercise, 5.5-year term.","H.C. Wainwright acts as placement agent; fees: 7% cash, 1% mgmt, 68,344 warrants.","Closing expected Nov 20, 2023; proceeds for clinical trials, patent portfolio, working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041982","json":"https://secwatch.observer/filing/0001493152-23-041982.json","markdown":"https://secwatch.observer/filing/0001493152-23-041982.md","text":"https://secwatch.observer/filing/0001493152-23-041982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223041982/0001493152-23-041982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223041982/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:18:14.590413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20c2a920a9d6678ccaf922aba6aa40607936e154","claim":"Bone Biologics Corp entered into Purchase Agreement with certain institutional investors valued at 1,139,063 shares of the Company's common stock, $0.001 par value per share, at an offering price of (effective 2023-11-16).","evidence_excerpt":"On November 16, 2023, Bone Biologics Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Registered Direct Offering”), 1,139,063 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at an offering price of $0.64 per Share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223041982/0001493152-23-041982-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"1,139,063 shares of the Company's common stock, $0.001 par value per share, at an offering price of"},{"label":"Effective","value":"2023-11-16"}],"fact_type":"material_agreement"},{"claim_id":"5253c66ad554bb011aa2c379bee9b15ff94b8f74","claim":"Bone Biologics Corp entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering and a management fee (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, the Company entered into an engagement agreement (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the exclusive placement agent in connection with the Offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223041982/0001493152-23-041982-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering and a management fee"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}